Small-Molecule Positive Allosteric Modulators of the -Adrenoceptor Isolated from DNA-Encoded Libraries.

Conventional drug discovery efforts at the -adrenoceptor (AR) have led to the development of ligands that bind almost exclusively to the receptor's hormone-binding orthosteric site. However, targeting the largely unexplored and evolutionarily unique allosteric sites has potential for developing more specific drugs with fewer side effects than orthosteric ligands. Using our recently developed approach for screening G protein-coupled receptors (GPCRs) with DNA-encoded small-molecule libraries, we have discovered and characterized the first AR small-molecule positive allosteric modulators (PAMs)-compound (Cmpd)-6 [()--(4-amino-1-(4-(-butyl)phenyl)-4-oxobutan-2-yl)-5-(-isopropyl--methylsulfamoyl)-2-((4-methoxyphenyl)thio)benzamide] and its analogs.

Allosteric "beta-blocker" isolated from a DNA-encoded small molecule library.

The β-adrenergic receptor (βAR) has been a model system for understanding regulatory mechanisms of G-protein-coupled receptor (GPCR) actions and plays a significant role in cardiovascular and pulmonary diseases. Because all known β-adrenergic receptor drugs target the orthosteric binding site of the receptor, we set out to isolate allosteric ligands for this receptor by panning DNA-encoded small-molecule libraries comprising 190 million distinct compounds against purified human βAR. Here, we report the discovery of a small-molecule negative allosteric modulator (antagonist), compound 15 [([4-((2)-3-((()-3-(3-bromophenyl)-1-(methylamino)-1-oxopropan-2-yl)amino)-2-(2-cyclohexyl-2-phenylacetamido)-3-oxopropyl)benzamide], exhibiting a unique chemotype and low micromolar affinity for the βAR.